Draft genome sequence of Priestia megaterium AB-S79 strain isolated from active gold mine.

We screened and isolated Priestia megaterium strain AB-S79 from active gold mine soil, then sequenced its genome to unravel its biosynthetic traits. The isolate with a 5.7-Mb genome can be utilized as a reference in genome-guided strain selection for metabolic engineering and other biotechnological operations.

Draft genome sequence of active gold mine isolate Pseudomonas iranensis strain ABS_30.

Pseudomonas iranensis ABS_30, isolated from gold mining soil, exhibits metal-resistant properties valuable for heavy metal removal. We report the draft genome sequencing of the P. iranensis ABS_30 strain, which is 5.9 Mb in size.

Evaluation of Pseudomonas fulva PS9.1 and Bacillus velezensis NWUMFkBS10.5 as Candidate Plant Growth Promoters during Maize-Fusarium Interaction.

Based on in vitro assessments, molecular and chemical analysis, Pseudomonas fulva PS9.1 and Bacillus velezensis NWUMFkBS10.5 are candidate biocontrol agents for plant disease management including maize fusariosis, a disease caused by members of the Fusarium species. This in vivo study evaluated the bio-protective potential of the aforementioned rhizobacteria strains on maize against the proliferation of the pathogenic fungus Fusarium graminearum (Fg). The study results show that the bacterized plants were not susceptible to Fg aggression and the antagonists displayed the capability to proliferate in the presence of other likely competing microflora. The screen-house data also suggest that the presence of resident soil microbiota impacted the activity of antagonists (PS9.1 and NWUMFkBS10.5). This variation was recorded in the soil treatments (sterilized and unsterilized soil). In all the experimental periods, bacterized maize plants with or without Fg inoculation significantly (p = 0.05) grew better in unsterilized soil. Besides, during the experimental periods, all the consortia treatments with or without Fg infection regardless of the soil used demonstrated appreciable performance. The result of this study suggests that the microbial agents can actively colonize the surface of their maize plant host, improve plant growth, and suppress the growth of phytopathogens. Considering their overall performance in this screen-house evaluation, P. fulva PS9.1 and B. velezensis NWUMFkBS10.5 have potential for field applications. All safety issues regarding their use under field conditions and risks associated with their extended-release into the environmental will, however, be assessed prior to further bioformulation, field investigation, and scale-up.

Elucidating the Antimycobacterial Mechanism of Action of Decoquinate Derivative RMB041 Using Metabolomics.

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), still remains one of the leading causes of death from a single infectious agent worldwide. The high prevalence of this disease is mostly ascribed to the rapid development of drug resistance to the current anti-TB drugs, exacerbated by lack of patient adherence due to drug toxicity. The aforementioned highlights the urgent need for new anti-TB compounds with different antimycobacterial mechanisms of action to those currently being used. An N-alkyl quinolone; decoquinate derivative RMB041, has recently shown promising antimicrobial activity against Mtb, while also exhibiting low cytotoxicity and excellent pharmacokinetic characteristics. Its exact mechanism of action, however, is still unknown. Considering this, we used GCxGC-TOFMS and well described metabolomic approaches to analyze and compare the metabolic alterations of Mtb treated with decoquinate derivative RMB041 by comparison to non-treated Mtb controls. The most significantly altered pathways in Mtb treated with this drug include fatty acid metabolism, amino acid metabolism, glycerol metabolism, and the urea cycle. These changes support previous findings suggesting this drug acts primarily on the cell wall and secondarily on the DNA metabolism of Mtb. Additionally, we identified metabolic changes suggesting inhibition of protein synthesis and a state of dormancy.

Elucidating the Antimycobacterial Mechanism of Action of Ciprofloxacin Using Metabolomics.

In the interest of developing more effective and safer anti-tuberculosis drugs, we used a GCxGC-TOF-MS metabolomics research approach to investigate and compare the metabolic profiles of Mtb in the presence and absence of ciprofloxacin. The metabolites that best describe the differences between the compared groups were identified as markers characterizing the changes induced by ciprofloxacin. Malic acid was ranked as the most significantly altered metabolite marker induced by ciprofloxacin, indicative of an inhibition of the tricarboxylic acid (TCA) and glyoxylate cycle of Mtb. The altered fatty acid, myo-inositol, and triacylglycerol metabolism seen in this group supports previous observations of ciprofloxacin action on the Mtb cell wall. Furthermore, the altered pentose phosphate intermediates, glycerol metabolism markers, glucose accumulation, as well as the reduction in the glucogenic amino acids specifically, indicate a flux toward DNA (as well as cell wall) repair, also supporting previous findings of DNA damage caused by ciprofloxacin. This study further provides insights useful for designing network whole-system strategies for the identification of possible modes of action of various drugs and possibly adaptations by Mtb resulting in resistance.

Genomic Exploration of Bacillus thuringiensis MORWBS1.1, Candidate Biocontrol Agent, Predicts Genes for Biosynthesis of Zwittermicin, 4,5-DOPA Dioxygenase Extradiol, and Quercetin 2,3-Dioxygenase.

Many strains from Bacillus thuringiensis are known for their genomic robustness and antimicrobial potentials. As a result, the quest for their biotechnological applications, especially in the agroindustry (e.g., as biopesticides), has increased over the years. This study documents the genome sequencing and probing of a Fusarium antagonist (B. thuringiensis strain MORWBS1.1) with possible biopesticidal metabolite producing capacity from South Africa. Based on in vitro evaluation and in silico antiSMASH investigation, B. thuringiensis strain MORWBS1.1 exhibited distinctive genomic properties that could be further exploited for in planta and food additive production purposes.[Formula: see text] Copyright © 2021 The Author(s). This is an open access article distributed under the CC BY-NC-ND 4.0 International license.

Genome Sequence Resource of Pseudomonas fulva HARBPS9.1-Candidate Biocontrol Agent.

The genus Pseudomonas contains a variety of genomic robust strains and species, well known for their beneficial use in a variety of applications, hence the vast amount of research done on this organism to date. We report here the draft genome sequence of an anti-Fusarium rhizospheric Pseudomonas fulva HARBPS9.1 strain from South Africa. This genome analysis identified clusters of genes responsible for the synthesis of pyoverdin and rhizomide in HARBPS9.1; these compounds should confer a competitive advantage on the pseudomonad.

Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus.

The latest WHO report estimates about 1.6 million global deaths annually from TB, which is further exacerbated by drug-resistant (DR) TB and comorbidities with diabetes and HIV. Exiguous dosing, incomplete treatment course, and the ability of the tuberculosis bacilli to tolerate and survive current first-line and second-line anti-TB drugs, in either their latent state or active state, has resulted in an increased prevalence of multidrug-resistant (MDR), extensively drug-resistant (XDR), and totally drug-resistant TB (TDR-TB). Although a better understanding of the TB microanatomy, genome, transcriptome, proteome, and metabolome, has resulted in the discovery of a few novel promising anti-TB drug targets and diagnostic biomarkers of late, no new anti-TB drug candidates have been approved for routine therapy in over 50 years, with only bedaquiline, delamanid, and pretomanid recently receiving tentative regulatory approval. Considering this, alternative approaches for identifying possible new anti-TB drug candidates, for effectively eradicating both replicating and non-replicating Mycobacterium tuberculosis, are still urgently required. Subsequently, several antibiotic and non-antibiotic drugs with known treatment indications (TB targeted and non-TB targeted) are now being repurposed and/or derivatized as novel antibiotics for possible use in TB therapy. Insights gathered here reveal that more studies focused on drug-drug interactions between licensed and potential lead anti-TB drug candidates need to be prioritized. This write-up encapsulates the most recent findings regarding investigational compounds with promising anti-TB potential and drugs with repurposing potential in TB therapy.

Genome Sequence of Lipopeptide- and Antioxidant-Producing Strain Bacillus velezensis NWUMFkBS10.5.

Candidate biocontrol agent Bacillus velezensis NWUMFkBS10.5 possesses unique genomic characteristics revealed by antiSMASH analysis and in vitro metabolomic elucidation. Besides its capability to produce antimicrobial lipopeptides, further in silico genome profiling predicted the presence of metabolic pathways for synthesizing antioxidants like lampranthin-2, miraxanthin V, and 2-decarboxybetanidin.